drugset / Trial / NCT00470496

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer

NCT00470496 ↗

Phase 1 Completed 15 enrolled Roswell Park Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer. Photodynamic therapy (PDT) uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Giving photodynamic therapy after surgery may kill any tumor cells that remain after surgery.

Timeline

Start
2006-10-19
Primary completion
2011-10-28
Completion
2018-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 4 mg/m2 Intravenous